Alder Biopharmaceuticals Inc  

(Public, NASDAQ:ALDR)   Watch this stock  
Find more results for ALDR
21.55
+0.20 (0.94%)
After Hours: 21.55 0.00 (0.00%)
Jan 17, 4:39PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.20 - 21.90
52 week 15.82 - 36.48
Open 21.05
Vol / Avg. 907,841.00/677,508.00
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -2.85
Shares 50.30M
Beta     -
Inst. own 118%
Feb 21, 2017
Q4 2016 Alder Biopharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 8, 2016
Alder Biopharmaceuticals Inc at Credit Suisse Healthcare Conference
Oct 27, 2016
Q3 2016 Alder Biopharmaceuticals Inc Earnings Call
Oct 27, 2016
Q3 2016 Alder Biopharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.70% -36.81%
Return on average equity -31.85% -38.27%
Employees 113 -
CDP Score - -

Address

11804 N Creek Pkwy S
BOTHELL, WA 98011-8801
United States - Map
+1-425-2052900 (Phone)
+1-425-2052901 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing's disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody.

Officers and directors

Stephen M. Dow Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Randall C. Schatzman Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Larry K. Benedict Principal Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 55
Bio & Compensation  - Reuters
Randal A. Hassler Senior Vice President - Pharmaceutical Operations
Age: 58
Bio & Compensation  - Reuters
Jeffrey T.L. Smith M.D. Senior Vice President, Translational Medicine
Age: 56
Bio & Compensation  - Reuters
John A. Latham Ph.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Mark James Litton Ph.D. Chief Business Officer, Treasurer and Secretary
Age: 48
Bio & Compensation  - Reuters
Paul Rutherford Carter Independent Director
Age: 55
Bio & Compensation  - Reuters
Paul B. Cleveland Independent Director
Age: 59
Bio & Compensation  - Reuters
A. Bruce Montgomery M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters